A first for CCR8
Cafelkibart’s entry into phase 3 is of note to Coherus.
Sanofi steps back from radioconjugates
The company quietly deprioritises AlphaMedix.
Revolution adds to its KRAS ambitions
RMC-5127 becomes the company’s fourth clinical project.
Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
The ranks of Rybrevant challengers swell
The line-up is revealed to include Merck & Co and J&J itself.
The month ahead: February’s upcoming events
Tecvayli and Hernexeos might get speedy approval decisions.
Pumitamig pivotal trials come in pairs
Bristol will test the bispecific in two new lung indications.
Cardiff goes south again
The latest onvansertib data, and an abrupt CEO departure, spook investors.
